Cencora (WBO:ABC) Other Current Liabilities: €803 Mil (As of Mar. 2026)


WBO:ABC Cencora Inc WBO:ABC
67 GF Score
Price €256.60
GF Value €252.90
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Cencora Other Current Liabilities?

Cencora WBO:ABC +2.15% 67 Other Current Liabilities is €803 Mil as of Mar. 2026. GuruFocus rates WBO:ABC with a GF Score™ of 67/100 and a GF Value™ of €252.90 (Fairly Valued). The stock has 1 warning sign investors should review.

Cencora's other current liabilities for the quarter that ended in Mar. 2026 was €803 Mil.

Cencora's quarterly other current liabilities increased from Sep. 2025 (€0 Mil) to Dec. 2025 (€0 Mil) and increased from Dec. 2025 (€0 Mil) to Mar. 2026 (€803 Mil).

Cencora's annual other current liabilities declined from Sep. 2023 (€0 Mil) to Sep. 2024 (€0 Mil) but then stayed the same from Sep. 2024 (€0 Mil) to Sep. 2025 (€0 Mil).

Cencora Other Current Liabilities Related Terms

Cencora Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Cencora's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cencora Other Current Liabilities Chart

Cencora Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 163.26 0.00 0.00 0.00 0.00

Cencora Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.06 112.81 0.00 0.00 802.89
WBO:ABC
67GF Score
Cencora Inc WBO:ABC
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cencora Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €803 Mil mean?
Cencora (WBO:ABC) has a Other Current Liabilities of €803 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cencora.
Is Cencora's Other Current Liabilities too high?
Cencora's current Other Current Liabilities is €803 Mil. Overall, Cencora has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's Other Current Liabilities compare to CAH and MCK?
Cencora's Other Current Liabilities of €803 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Distribution company?
A good Other Current Liabilities depends on the Medical Distribution industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Cencora. Cencora's current Other Current Liabilities is €803 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €252.90, compared to a current price of €256.60 — trading 1.5% above its estimated fair value. The current Other Current Liabilities is €803 Mil. Cencora's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Cencora (WBO:ABC), the current Other Current Liabilities is €803 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cencora (WBO:ABC) Overvalued in 2026?

Based on GuruFocus' analysis, Cencora stock appears to be overvalued. The current stock price of €256.60 is trading 1.5% above its estimated GF Value™ of €252.90. GuruFocus considers Cencora to be Fairly Valued.

Key valuation signals for WBO:ABC:

  • Other Current Liabilities: €803 Mil
  • GF Value™: €252.90 vs. price of €256.60 (1.5% above fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cencora Business Description

Address 1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
67GF Score

Get the complete analysis for WBO:ABC

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€256.60
Price
€252.90
GF Value